Protocol Ledger

NCT05987332 · Phase II/III · ACTIVE NOT RECRUITING

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Interventional Phase II/III clinical trial protocol NCT05987332 sponsored by IDEAYA Biosciences in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-10-31 Enrollment: 420 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05987332
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)420 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05987332
Protocol FieldVerified Registry Value
NCT IdentifierNCT05987332
Consolidated Lead SponsorIDEAYA Biosciences
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment420 participants (ESTIMATED)
Registered Start Date2023-10-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI